Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2013

Summary of Significant Accounting Policies

Summary of the activity of reserve for each of the major category of revenue allowance

For the nine months ended March 31, 2013

(In thousands)
Reserve Category	Chargebacks			Rebates			Returns			Other			Total
Reserve Balance as of July 1, 2012	$	7,063		$	4,436		$	5,540		$	—		$	17,039
Actual credit issued related to sales recorded in prior fiscal years	(6,586		)	(4,434		)	(2,521		)	(66		)	(13,607		)
Reserve or (reversal) charged during Fiscal 2013 related to sales in prior fiscal years	(463		)	139			—			66			(258		)
Reserve charged to net sales during Fiscal 2013 related to sales recorded in Fiscal 2013	52,006			17,467			3,363			2,801			75,637
Actual credit issued related to sales recorded in Fiscal 2013	(45,542		)	(13,918		)	—			(2,801		)	(62,261		)
Reserve Balance as of March 31, 2013	$	6,478		$	3,690		$	6,382		$	—		$	16,550

For the nine months ended March 31, 2012

(In thousands)
Reserve Category	Chargebacks			Rebates			Returns			Other			Total
Reserve Balance as of July 1, 2011	$	5,497		$	2,925		$	5,142		$	—		$	13,564
Actual credit issued related to sales recorded in prior fiscal years	(5,350		)	(3,084		)	(3,426		)	(152		)	(12,012		)
Reserve or (reversal) charged during Fiscal 2012 related to sales in prior fiscal years	(54		)	158			—			152			256
Reserve charged to net sales during Fiscal 2012 related to sales recorded in Fiscal 2012	50,392			15,405			3,567			488			69,852
Actual credit issued related to sales recorded in Fiscal 2012	(44,092		)	(11,686		)	—			(488		)	(56,266		)
Reserve Balance as of March 31, 2012	$	6,393		$	3,718		$	5,283		$	—		$	15,394

Summary of net product sales by medical indication

(In thousands)	For the Three Months Ended March 31,				For the Nine Months Ended March 31,
Medical Indication	2013		2012		2013		2012
Antibiotic	$	3,496	$	1,662	$	6,267	$	4,798
Cardiovascular	6,988		6,050		21,356		11,512
Gallstone	1,390		1,419		4,676		4,286
Glaucoma	1,627		993		4,608		3,093
Gout	1,776		110		2,907		482
Migraine Headache	1,299		1,442		3,995		4,601
Obesity	1,074		979		3,488		2,570
Pain Management	4,980		4,043		14,752		14,609
Thyroid Deficiency	14,024		12,543		42,135		36,788
Other	2,368		1,447		6,696		4,561
Total	$	39,022	$	30,688	$	110,880	$	87,300

Summary of products which accounted for at least 10% of net sales

	For the Three Months Ended March 31,				For the Nine Months Ended March 31,
	2013		2012		2013		2012
Product 1	36	%	41	%	38	%	42	%
Product 2	12	%	11	%	11	%	4	%
Product 3	10	%	6	%	9	%	9	%

Summary of customers which accounted for at least 10% of net sales

	For the Three Months Ended March 31,				For the Nine Months Ended March 31,
	2013		2012		2013		2012
Customer A	16	%	16	%	16	%	18	%
Customer B	11	%	10	%	12	%	11	%
Customer C	10	%	9	%	10	%	12	%
Customer D	9	%	11	%	8	%	10	%